Overview

Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

Status:
Recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

MAMOC is a multicenter, randomized, placebo controlled, double blind study including BRCA negative patients with histologically confirmed, advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classification) high grade serous or high grade endometrioid (based on local histopathological findings) ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary in first line therapy.

Phase:

Phase 3

Details

Lead Sponsor:

North Eastern German Society of Gynaecological Oncology

Collaborators:

Clovis Oncology, Inc.
IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Treatments:

Bevacizumab
Carboplatin
Rucaparib